P622. In a Dutch real-life inflammatory bowel disease score cohort with 90% prior anti-tumour necrosis factor failure, vedolizumab showed a 25% remission rate: a retrospective multicentre study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.